The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades mRNA vaccine-induced antibodies with high efficiency

The key takeaway:

A.30 exhibits a cell line preference not observed for other viral variants and efficiently evades neutralization by antibodies elicited by ChAdOx1 nCoV-19 or BNT162b2 vaccination.

In short, A.30 evades the mRNA vaccines and should be monitored closely.

See and